A plasmonic biosensor pre-diagnostic tool for Familial Mediterranean Fever

Idil Karaca Acari, Fatma Kurul, Meryem Beyza Avci, S. Deniz Yasar, Seda Nur Topkaya, Ceyhun Açarı, Erbil Ünsal, Balahan Makay, Süleyman Köytepe, Burhan Ateş, İsmet Yilmaz, Turgay Seçkin and Arif E. Cetin ()
Additional contact information
Idil Karaca Acari: Malatya Turgut Ozal University
Fatma Kurul: Izmir Biomedicine and Genome Center
Meryem Beyza Avci: Izmir Biomedicine and Genome Center
S. Deniz Yasar: Izmir Biomedicine and Genome Center
Seda Nur Topkaya: Izmir Katip Celebi University
Ceyhun Açarı: Inonu University
Erbil Ünsal: Dokuz Eylul University
Balahan Makay: Dokuz Eylul University
Süleyman Köytepe: Inonu University
Burhan Ateş: Inonu University
İsmet Yilmaz: Inonu University
Turgay Seçkin: Inonu University
Arif E. Cetin: Izmir Biomedicine and Genome Center

Nature Communications, 2024, vol. 15, issue 1, 1-17

Abstract: Abstract Familial Mediterranean Fever (FMF) is an autosomal recessive genetic disorder, primarily observed in populations around the Mediterranean Sea, linked to MEFV gene mutations. These mutations disrupt inflammatory responses, increasing pyrin-protein production. Traditional diagnosis relies on clinical symptoms, family history, acute phase reactants, and excluding similar syndromes with MEFV testing, which is expensive and often inconclusive due to heterozygous mutations. Here, we present a biosensor platform that detects differences in pyrin-protein levels between healthy and affected individuals, offering a cost-effective alternative to genetic testing. Our platform uses gold nanoparticle-based plasmonic chips enhanced with anti-pyrin antibodies, achieving a detection limit of 0.24 ng/mL with high specificity. The system integrates an optofluidic system and visible light spectroscopy for real-time analysis, with signal stability maintained for up to six months. Our technology will enhance FMF diagnosis accuracy, enabling early treatment initiation and providing a cost-effective alternative to genetic testing, thus improving patient care.

Date: 2024
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-024-52961-8 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:15:y:2024:i:1:d:10.1038_s41467-024-52961-8

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-024-52961-8

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().